JAK2 and acute myeloid leukemia: Activating the mutation of FLT3 and JAK2 (e.g., V617F), as well as the functional loss of the suppressor of cytokine signaling-1 (SOCS1) leads to the constitutive activation of JAK2-STAT5 signaling in AML [135].